Home » Stocks » EDSA

Edesa Biotech, Inc. (EDSA)

Stock Price: $6.38 USD 0.40 (6.69%)
Updated May 7, 2021 4:00 PM EDT - Market closed
Market Cap 84.08M
Revenue (ttm) 221,001
Net Income (ttm) -7.93M
Shares Out 13.18M
EPS (ttm) -0.73
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $6.38
Previous Close $5.98
Change ($) 0.40
Change (%) 6.69%
Day's Open 6.01
Day's Range 5.97 - 6.70
Day's Volume 308,793
52-Week Range 2.45 - 19.10

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Virtual event scheduled for Thursday, April 29 at 1 pm Eastern Time TORONTO, ON / ACCESSWIRE / April 22, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on i...

2 weeks ago - Accesswire

TORONTO, ON / ACCESSWIRE / March 22, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that it has...

1 month ago - Accesswire

TORONTO, ON / ACCESSWIRE / March 15, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that it has...

1 month ago - Accesswire

TORONTO, ON / ACCESSWIRE / March 9, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that it has ...

1 month ago - Accesswire

TORONTO, ON / ACCESSWIRE / March 2, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced the closing ...

2 months ago - Accesswire

Among the biopharma movers of the day are immunology company Vir Biotechnology Inc (NASDAQ: VIR) and Edesa Biotech Inc (NASDAQ: EDSA), which focuses on developing therapies for inflammatory and immune-r...

3 months ago - Benzinga

TORONTO, ON / ACCESSWIRE / January 11, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, has received approval from the Ministry of Health (INVIMA) in Colombia to exp...

3 months ago - Accesswire

TORONTO, ON / ACCESSWIRE / December 30, 2020 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, issued a letter to shareholders from its Chief Executive Officer, Par Nijhaw...

4 months ago - Accesswire

Edesa Biotech Inc. (NASDAQ: EDSA) joins the list of COVID-19 stocks, as the company is making headway with regulatory agencies for its late-stage study.

9 months ago - 24/7 Wall Street

Canadian biopharma Edesa Biotech Inc (NASDAQ: EDSA) is seeing its shares surge higher Monday after it announced regulatory approval to begin a late-stage study of its investigational asset for COVID-19.

10 months ago - Benzinga

Edesa Biotech received go ahead from FDA to initiate its phase 2b study using EB01 to treat patients with chronic contact dermatitis.

1 year ago - Seeking Alpha

Edesa Biotech (EDSA) stock is flying higher on Thursday after getting approval from the U.S. Food and Drug Administration (FDA).

1 year ago - InvestorPlace

Edesa Biotech Inc., shares were trading higher Thursday after the company received Food and Drug Administration approval to proceed with its U.S.

1 year ago - Benzinga

About EDSA

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 2/Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical cream containing non-steroidal anti-inflammatory compound that is in Phase 2B clinical study to treat chronic allergic contact dermat... [Read more...]

Industry
Biotechnology
Founded
2015
Stock Exchange
NASDAQ
Ticker Symbol
EDSA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to one analyst, the rating for Edesa Biotech stock is "Strong Buy" and the 12-month stock price forecast is 17.00.

Price Target
$17.00
Analyst Consensus: Strong Buy